Enterprise Value
124.8M
Cash
56.33M
Avg Qtr Burn
-9.705M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
51.68%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MPH-966 (Alvelestat) (oral neutrophil elastase inhibitor) Details Bronchiolitis Obliterans Syndrome | Phase 2 Data readout | |
Setrusumab Details Osteogenesis imperfecta | Phase 2 Data readout | |
MPH-966 (Alvelestat) (oral neutrophil elastase inhibitor) Details Severe alpha-1 antitrypsin deficiency Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Phase 1/2 Update | ||
Etigilimab (MPH-313)(Antibody against TIGIT) Details Solid tumor/s, Cancer | Phase 1b Data readout | |
Etigilimab Details Ovarian cancer | Phase 1b Update |